Navigation Links
Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932
Date:2/16/2012

LAUSANNE, Switzerland and LEXINGTON, Massachusetts, February 16, 2012 /PRNewswire/ --

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, and Debiopharm Group (Debiopharm), a group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that Debiopharm has begun treating patients in a Phase Ib clinical trial of Heat Shock Protein 90 (HSP90) inhibitor Debio 0932. Debiopharm recently successfully completed a Phase Ia dose escalation study with Debio 0932 and has indicated that it expects to initiate a combination Phase I/II study in non-small cell lung cancer patients in the second quarter of 2012.

"Our team has been very pleased with the development of Debio 0932, which has become an important molecule in Debiopharm's pipeline," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group. "We believe that HSP90 represents an important molecular target in cancer therapy, and we are eager to advance this molecule in the Phase Ib clinical trial, as well in our planned Phase I/II studies, which we hope will yield important new data for the further development of Debio 0932."

"We have been highly impressed with the depth of Debiopharm's development expertise and commitment to furthering Debio 0932 into additional clinical studies in 2012," said Dan Passeri, Curis President and Chief Executive Officer. "Importantly, we continue to be very pleased with the clinical results that have been observed to-date, and we look forward to reporting further progress on this molecule in the future."

About the Phase I Clinical Trial

Debiopharm initiated a Phase I clinical trial in April 2010 that was designed to evaluate the maximum tolerated dose and safety of Debio 0932. The first part of the study (Phase Ia), an open-label,
'/>"/>

SOURCE The Debiopharm Group and Curis Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Augurix Diagnostics Receives the 2011 Debiopharm /Valais Award for its Point-of-care Diagnostic Test for the Early Detection of Celiac Disease
2. Continuity as Debiopharm Group™ Management Moves Forward
3. The Japanese Cancer Association and Debiopharm Group(TM) Present the JCA-Mauvernay Award to Dr Ogawa and Prof. Maeda for Their Outstanding Oncology Research
4. Debiopharm Group™ and Aurigene Nominate Development Candidate
5. Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025
6. The Japanese Cancer Association and Debiopharm Group Present the JCA-Mauvernay Award to Dr Ushijima for his Oncology Research
7. Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930
8. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
9. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
10. Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries
11. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Aug. 4, 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: ... the development and commercialization of targeted antiviral therapies, ... Officer, will present live at VirtualInvestorConferences.com on August ... 2015 TIME: 12:15PM EDT LINK: http://tinyurl.com/aug6-pre-ctrv ... interactive online event where investors are invited to ...
(Date:8/4/2015)... Ltd. (NASDAQ: ELOS ), a leading global aesthetic device ... ended June 30, 2015. Second Quarter ... , Revenue of $73.5 million, up 14% year-over-year, or ... grew 45% year-over-year. , International sales grew 8% year-over-year, ... the EMEA region and 25% product growth in the Asia-Pacific ...
(Date:8/3/2015)... GLENWOOD, Ill. , Aug. 3, 2015  Landauer, ... personal and environmental radiation measurement and monitoring, outsourced medical ... announced it will release financial results for the fiscal ... August 10, 2015. The Company will ... August 11, 2015 at 9:00 a.m. Central Time (10:00 ...
Breaking Medicine Technology:ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 2Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 4Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 5Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 6Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 7Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 8Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 9Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 10Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 11Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 12Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 13Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 14Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 15Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 16Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 17Landauer, Inc. Announces Date And Time For Announcement Of Fiscal Third Quarter 2015 Results And Conference Call 2
(Date:8/4/2015)... ... August 04, 2015 , ... Oriental Trading Company, ... toys, novelties, and school supplies, has developed engaging and affordable teacher supplies based ... includes student rewards, classroom decorations, crafts and educational resources featuring Carle’s vibrant ...
(Date:8/4/2015)... ... , ... It is National Psoriasis Awareness Month, and we are reminded that ... dry, itching, burning or soreness of skin that may crack or bleed. , Typically, ... right for them. Then, what is effective may stop working, so they have to ...
(Date:8/4/2015)... ... August 04, 2015 , ... The goal of looking younger ... desire for invasive surgery to achieve this ideal is not. But minimally invasive procedures ... without the high cost or lengthy recovery time, according to Valerie Goldburt, MD, ...
(Date:8/4/2015)... , ... August 04, 2015 , ... Nathan’s Famous ... takes a look small, medium, and large businesses making an impact in their industry. ... shared with viewers how the famous hot dog maker now offers a 50% ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... the most recent episode which spotlights treating depression. Depression affects millions of Americans ... "In America" wants to inform and enlighten viewers with the latest segment produced ...
Breaking Medicine News(10 mins):Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 2Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 3Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 2Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 3Health News:Considering fillers, tighteners or laser resurfacing? 2Health News:Considering fillers, tighteners or laser resurfacing? 3Health News:Considering fillers, tighteners or laser resurfacing? 4Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 2Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 3
... Customer Diversity and Related Strategic Opportunities , , ... has named Carolyn H. Clift as senior vice president ... be responsible for leading the company,s diversity-related strategic operations ... and fourth largest health insurer overall, HCSC has been ...
... the Implicit Association Test was introduced, its most surprising ... percent of those who took a version of the ... implicit, preference for white people compared to blacks. ... self report, or survey, measures of race bias. A ...
... and Low Metals Levels Cited as Key Reasons ... 17 Valensa International has selected Parry Nutraceuticals, ... for its range of new value-added nutrition products. ... phyto-nutrients that consumers want from their spirulina products ...
... sheds light on cause of lethal cancer, expert says, , ... genetic trait that appears to boost the risk that a ... system. , The findings don,t point toward a treatment, but ... co-author Dr. John Maris. , "We,ve learned a lot more ...
... the National Multiple Sclerosis Society - Wisconsin Chapter recognized ... Appreciation Award. The recognition commends Dr. Khatri for his ... research to treat it. , , (Logo: ... receive this recognition," says Dr. Khatri, medical director of ...
... executive director of the President,s Council on Physical Fitness ... and inventor George P. Nissen; and Olympic coach Dr. ... Achievement Awards given annually by the President,s Council. , ... to individuals whose careers have greatly contributed to the ...
Cached Medicine News:Health News:Health Care Service Corporation Names Carolyn H. Clift as Senior Vice President and First Chief Diversity Officer 2Health News:Study supports validity of test that indicates widespread unconscious bias 2Health News:Valensa Selects Parry Organic Spirulina as Ingredient of Choice for Premium Product Development 2Health News:Valensa Selects Parry Organic Spirulina as Ingredient of Choice for Premium Product Development 3Health News:Valensa Selects Parry Organic Spirulina as Ingredient of Choice for Premium Product Development 4Health News:Genes May Raise Risk of Neuroblastoma in Kids 2Health News:Genes May Raise Risk of Neuroblastoma in Kids 3Health News:Aurora Physician Recognized for Multiple Sclerosis Care 2Health News:The President's Council on Physical Fitness and Sports Announces 2009 Lifetime Achievement Award Winners 2Health News:The President's Council on Physical Fitness and Sports Announces 2009 Lifetime Achievement Award Winners 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: